Sunshine Biopharma Receives Notification Letter From The Nasdaq Stock Market Granting The Company's Request For An Exception Until August 26, 2024, To Regain Compliance
Sunshine Biopharma Receives Notification Letter From The Nasdaq Stock Market Granting The Company's Request For An Exception Until August 26, 2024, To Regain Compliance
世紀陽光生物製藥公司收到了納斯達克證券交易所發出的通知函,同意公司請求將期限延長至2024年8月26日以恢復合規性。
On June 28, 2024, Sunshine Biopharma, Inc. (the "Company") received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"), informing the Company that the Nasdaq Hearings Panel has granted the Company's request for an exception until August 26, 2024, to regain compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2)
2024年6月28日,世紀陽光生物醫藥公司(以下簡稱“公司”)收到了納斯達克證券市場有限責任公司(以下簡稱“納斯達克”)的一封通知信,通知公司納斯達克聽證小組已經批准了公司的請求,延期至2024年8月26日,以符合納斯達克5550(a)(2)條目下的最低買盤要求。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。